Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer will buy Merck’s shares in Schering AG at €89 per share, or €3 more than the current bid.
You may also be interested in...
Bayer Schering Pharma SVP-Global Business Development And Licensing Michael Yeomans: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Yeomans discusses how the firm’s increasing biologics capabilities fits into Bayer Schering’s business development strategy and the growing importance of Asia to the company.
Bayer Schering Pharma SVP-Global Business Development And Licensing Michael Yeomans: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Yeomans discusses how the firm’s increasing biologics capabilities fits into Bayer Schering’s business development strategy and the growing importance of Asia to the company.
Bayer Schering Abandons Higher Dose Betaferon Following Disappointing Data
Head-to-head trial against Teva’s Copaxone in MS failed to show statistically significant superiority.